While circulating cell-free DNA (ccfDNA), and to some extent circulating tumor cells (CTCs) from blood are routinely used as analytes in liquid biopsy cancer research applications, circulating cell-free RNA (ccfRNA) has recently also gained relevance for biomarker studies. The combination of insights from different analytes promises increased understanding of molecular processes in tumor biology. However, there are still challenges to overcome in the preanalytical workflow, such as defining suitable blood collection tubes for optimal assay sensitivity. In this session, we show the multianalyte use of the PAXgene Blood ccfDNA Tube (RUO) for plasma extraction as part of a liquid biopsy workflow. Learning objectives: the need for blood stabilization for ccfDNA analysis and impact on assay sensitivity and multianalyte applications for liquid biopsy research.

While circulating cell-free DNA (ccfDNA), and to some extent circulating tumor cells (CTCs) from blood are routinely used as analytes in liquid biopsy cancer research applications, circulating cell-free RNA (ccfRNA) has recently also gained relevance for biomarker studies. The combination of insights from different analytes promises increased understanding of molecular processes in tumor biology. However, there are still challenges to overcome in the preanalytical workflow, such as defining suitable blood collection tubes for optimal assay sensitivity. In this session, we show the multianalyte use of the PAXgene Blood ccfDNA Tube (RUO) for plasma extraction as part of a liquid biopsy workflow. Learning objectives: the need for blood stabilization for ccfDNA analysis and impact on assay sensitivity and multianalyte applications for liquid biopsy research.